A Review of Hormone and Non-Hormonal Therapy Options for the Treatment of Menopause

Abstract Understanding the role of both menopausal hormone therapy (MHT) along with non-hormonal options for the treatment of vasomotor symptoms, sleep disruption, and genitourinary symptoms after menopause is critical to the health of women during middle and later life. Recent updates to the evidence for the treatment of menopausal symptoms pertaining to both hormonal and non-hormonal therapies as well as updated guidance from specialty societies can help guide clinicians in their treatment of women going through natural menopause or with estrogen deficiencies due to primary ovarian insufficiency or induced menopause from surgery or medications. The objective of this narrative review is to provide clinicians with an overview of MHT for the use of menopausal symptoms in women, incorporating updated primary evidence for risk versus benefit profiles, recent specialty society recommendations, and alternative, non-hormonal options. In this review, we summarize literature on the use of MHT for menopause-related symptomatology including options for formulations and dosages of MHT, non-hormonal treatment options, and the risk–benefit profile of MHT including long-term health consequences (eg, cardiovascular disease, cognitive decline, venous thromboembolism, and fracture risk). Finally, we highlight areas in which future research is needed to advance care of women after menopause. In summary, both hormonal (MHT) and non-hormonal options exist to treat symptoms of menopause. There is strong evidence for safety and effectiveness of MHT for the treatment of vasomotor symptoms among women who are less than 60 years of age, less than 10 years since menopause, and without significant cardiometabolic comorbidities. For others, treatment with hormonal versus non-hormonal therapies can be considered based on individual risk profiles, as well as other factors such as drug formulation, therapeutic goals, and symptom severity.

[1]  R. Thurston,et al.  Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study , 2023, The Lancet.

[2]  R. Lobo.  The 2022 hormone therapy position statement of The North American Menopause Society. , 2022, Menopause.

[3]  G. Neal-Perry,et al.  Phase 3 Study of Fezolinetant for Treatment of Moderate-to-Severe Vasomotor Symptoms Associated With Menopause [A132] , 2022, Obstetrics & Gynecology.

[4]  J. Manson,et al.  Serum follicle stimulating hormone and five-year change in adiposity in healthy postmenopausal women. , 2022, The Journal of clinical endocrinology and metabolism.

[5]  Maya B. Mathur,et al.  Menopausal hormone therapy and women’s health: An umbrella review , 2021, PLoS medicine.

[6]  D. Poyares,et al.  Hot flashes, insomnia, and the reproductive stages: a cross-sectional observation of women from the EPISONO study. , 2021, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.

[7]  R. Beverly,et al.  Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women , 2021 .

[8]  Theresa M. Beckie,et al.  Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. , 2020, Circulation.

[9]  James B. Young,et al.  Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA) , 2020, Menopause.

[10]  J. Manson,et al.  Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials. , 2020, JAMA.

[11]  Louis A. Pagliaro,et al.  Paroxetine , 2020, Reactions Weekly.

[12]  K. Matthews,et al.  Does mid-life aging impact women's sleep duration, continuity, and timing?: A longitudinal analysis from the Study of Women's Health Across the Nation. , 2020, Sleep.

[13]  C. Champagne,et al.  Racial differences in body composition and cardiometabolic risk during the menopause transition: a prospective, observational cohort study. , 2020, American journal of obstetrics and gynecology.

[14]  V. Beral,et al.  Menopausal hormone therapy and 20-year breast cancer mortality , 2019, The Lancet.

[15]  K. Matthews,et al.  The menopause transition and women's health at midlife: a progress report from the Study of Women's Health Across the Nation (SWAN) , 2019, Menopause.

[16]  V. Beral,et al.  Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence , 2019, The Lancet.

[17]  D. Grigoraș,et al.  Surgically Induced Menopause—A Practical Review of Literature , 2019, Medicina.

[18]  A. Graziottin,et al.  Hormone therapy for first-line management of menopausal symptoms: Practical recommendations , 2019, Women's health.

[19]  J. Manson,et al.  Association of Normal-Weight Central Obesity With All-Cause and Cause-Specific Mortality Among Postmenopausal Women , 2019, JAMA network open.

[20]  J. Hippisley-Cox,et al.  Anticholinergic Drug Exposure and the Risk of Dementia , 2019, JAMA internal medicine.

[21]  J. Manson,et al.  The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned? , 2019, Menopause.

[22]  Y. Vinogradova.  Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases , 2019, British Medical Journal.

[23]  J. Hippisley-Cox,et al.  Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases , 2019, British Medical Journal.

[24]  S. Crawford,et al.  Menopausal hormone therapy trends before versus after 2002: impact of the Women's Health Initiative Study Results. , 2019, Menopause.

[25]  R. Thurston,et al.  Cardiovascular Implications of the Menopause Transition: Endogenous Sex Hormones and Vasomotor Symptoms. , 2018, Obstetrics and gynecology clinics of North America.

[26]  A. Dobson,et al.  Relationships between intensity, duration, cumulative dose, and timing of smoking with age at menopause: A pooled analysis of individual data from 17 observational studies , 2018, PLoS medicine.

[27]  P. Spritzer,et al.  Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis. , 2018, Thrombosis research.

[28]  Sanjiv J. Shah,et al.  Relation of Sex Hormone Levels With Prevalent and 10-Year Change in Aortic Distensibility Assessed by MRI: The Multi-Ethnic Study of Atherosclerosis , 2018, American journal of hypertension.

[29]  J. Manson,et al.  Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials , 2017, JAMA.

[30]  J. Manson,et al.  The 2017 hormone therapy position statement of The North American Menopause Society , 2017, Menopause.

[31]  P. Tobler,et al.  Ovarian hormones and obesity. , 2017, Human reproduction update.

[32]  J. Eden.  The endometrial and breast safety of menopausal hormone therapy containing micronised progesterone: A short review , 2017, The Australian & New Zealand journal of obstetrics & gynaecology.

[33]  A. Grauer,et al.  Romosozumab Treatment in Postmenopausal Women with Osteoporosis. , 2016, The New England journal of medicine.

[34]  V. Henderson,et al.  Cognitive effects of estradiol after menopause , 2016, Neurology.

[35]  Wendy J Mack,et al.  Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. , 2016, The New England journal of medicine.

[36]  M. Murad,et al.  Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. , 2015, The Journal of clinical endocrinology and metabolism.

[37]  Frederick Naftolin,et al.  Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS–Cognitive and Affective Study , 2015, PLoS medicine.

[38]  S. Crawford,et al.  Duration of menopausal vasomotor symptoms over the menopause transition. , 2015, JAMA internal medicine.

[39]  Sascha Dublin,et al.  Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. , 2015, JAMA internal medicine.

[40]  S. Wisniewski,et al.  Symptoms of depressed mood, disturbed sleep, and sexual problems in midlife women: cross-sectional data from the Study of Women's Health Across the Nation. , 2015, Journal of women's health.

[41]  M. Binkowska.  Menopausal hormone therapy and venous thromboembolism , 2014, Przeglad menopauzalny = Menopause review.

[42]  K. Moreau,et al.  Vascular Aging across the Menopause Transition in Healthy Women , 2014, Advances in vascular medicine.

[43]  Lewis H Kuller,et al.  Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. , 2013, JAMA.

[44]  J. Simon,et al.  Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials , 2013, Menopause.

[45]  Jennifer G. Robinson,et al.  Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. , 2013, JAMA internal medicine.

[46]  A. Pines.  Climacteric Commentaries , 2013, Climacteric : the journal of the International Menopause Society.

[47]  A. Trentham-Dietz,et al.  A Sustained Decline in Postmenopausal Hormone Use: Results From the National Health and Nutrition Examination Survey, 1999–2010 , 2012, Obstetrics and gynecology.

[48]  R. Kane,et al.  Benefits and Harms of Pharmacologic Treatment for Urinary Incontinence in Women , 2012, Annals of Internal Medicine.

[49]  S. Crawford,et al.  Trajectory clustering of estradiol and follicle-stimulating hormone during the menopausal transition among women in the Study of Women's Health across the Nation (SWAN). , 2012, The Journal of clinical endocrinology and metabolism.

[50]  P. Sluss,et al.  Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. , 2012, The Journal of clinical endocrinology and metabolism.

[51]  E. Gold.  The timing of the age at which natural menopause occurs. , 2011, Obstetrics and gynecology clinics of North America.

[52]  N. Santoro,et al.  Reproductive hormones and the menopause transition. , 2011, Obstetrics and gynecology clinics of North America.

[53]  D. Carroll,et al.  Use of Gabapentin for the Management of Natural or Surgical Menopausal Hot Flashes , 2011, The Annals of pharmacotherapy.

[54]  A. Schatzkin,et al.  Menopausal Hormone Therapy and Risk of Colorectal Cancer , 2009, Cancer Epidemiology Biomarkers & Prevention.

[55]  E. Oger,et al.  Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study , 2007, Circulation.

[56]  J. Buring,et al.  Effects of Conjugated Equine Estrogen on Stroke in the Women’s Health Initiative , 2006, Circulation.

[57]  A. Verbeek,et al.  Age at Menopause, Cause-Specific Mortality and Total Life Expectancy , 2005, Epidemiology.

[58]  L. Patterson,et al.  Effects of conjugated equine estrogen in postmenopausal women with hysterectomy , 2004, Journal of Family Planning and Reproductive Health Care.

[59]  JoAnn E Manson,et al.  Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. , 2004, JAMA.

[60]  L. Thal,et al.  Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study , 2004, JAMA.

[61]  John Robbins,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[62]  R. Chlebowski,et al.  Estrogen plus progestin and colorectal cancer in postmenopausal women. , 2004, The New England journal of medicine.

[63]  A. LaCroix,et al.  Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. , 2003, JAMA.

[64]  E. Oger,et al.  Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk , 2003, The Lancet.

[65]  C. Kooperberg,et al.  Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. , 2003, JAMA.

[66]  Robert B Wallace,et al.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003, JAMA.

[67]  Leslie Carol Botha.  Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women , 2003 .

[68]  E. Perez,et al.  Pilot evaluation of gabapentin for treating hot flashes. , 2002, Mayo Clinic proceedings.

[69]  E. Vittinghoff,et al.  Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study , 2000, Annals of Internal Medicine.

[70]  J. Carson,et al.  Risk of venous thromboembolism in users of hormone replacement therapy , 1996, The Lancet.

[71]  J. Manson,et al.  Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. , 1996, The New England journal of medicine.

[72]  K. Kerlikowske,et al.  Hormone replacement therapy and endometrial cancer risk: a meta-analysis. , 1995, Obstetrics and gynecology.

[73]  J. Manson,et al.  Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. , 1991, The New England journal of medicine.